Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Robert Reindollar
Peginterferon Alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis
New England Journal of Medicine
Medicine
Related publications
PGI18 Treatment of Chronic Hepatitis C Patients With Peginterferon Alfa-2a or Peginterferon Alfa-2b: A Cost-Effectiveness Analysis for the Portuguese NHS Setting
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Treatment With Peginterferon-Alfa-2a Versus Peginterferon-Alfa-2b for Patients With Chronic Hepatitis C Under the Public Payer Perspective in Brazil
Cost Effectiveness and Resource Allocation
Health Policy
Virological Response to Treatment With Peginterferon Alfa-2a in Adolescents With Chronic Hepatitis B.
Acta Biochimica Polonica
Biochemistry
Genetics
Molecular Biology
Peginterferon Alfa-2b and Ribavirin Therapy in Kuwaiti Patients With Chronic Hepatitis C Virus Infection
Eastern Mediterranean Health Journal
Medicine
Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C
Gastroenterology
Hepatology
Gastroenterology
Peginterferon Alfa-2a Is Associated With Elevations in Alanine Aminotransferase at the End of Treatment in Chronic Hepatitis C Patients With Sustained Virologic Response
PLoS ONE
Multidisciplinary
Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study
Hepatology
Medicine
Hepatology
Impact of Pegylated Interferon-Alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study
Hepatitis Monthly
Hepatology
Infectious Diseases
Serum Hepatitis B Virus RNA Levels as a Predictor of HBeAg Seroconversion During Treatment With Peginterferon Alfa-2a
Virology Journal
Virology
Infectious Diseases
